Please assess the completion status of the following clinical trial:

Trial Title: Rapamycin for Prevention of Chronic Graft-Versus-Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Received an allogeneic MSD or MUD PBSCT~* 24 weeks post SCT~* Currently on Tacrolimus for GVHD prophylaxis~* Deemed eligible for tapering off of Tacrolimus by primary BMT physician~Exclusion Criteria:~* Relapsed Disease~* Ongoing GVHD~* Patients whose immunosuppression is being stopped early to treat or prevent relapse~* Patients with pure red cell aplasia due to ABO mismatched donor~* Ongoing thrombotic microangiopathy~* Allergy to rapamycin~* Women of childbearing potential must have a negative serum pregnancy test performed prior to the start of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).